Single‐dose Pharmacokinetics of Eluxadoline in Healthy Participants With Normal Renal Function and Participants With Renal Impairment

Eluxadoline is approved for the treatment of diarrhea‐predominant irritable bowel syndrome in the United States. The impact of renal impairment on the pharmacokinetic (PK) parameters of eluxadoline is currently unknown. This phase 1, open‐label, parallel‐group study evaluated the PK and safety profi...

Descripción completa

Detalles Bibliográficos
Autores principales: Boinpally, Ramesh, Weissman, Darren
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2022
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108264/
https://www.ncbi.nlm.nih.gov/pubmed/36504331
http://dx.doi.org/10.1002/cpdd.1204

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10108264/
https://www.ncbi.nlm.nih.gov/pubmed/36504331
http://dx.doi.org/10.1002/cpdd.1204

Ejemplares similares